Navigation Links
Ikaria Appoints Daniel Tasse as President and Chief Executive Officer
Date:1/9/2008

- Former CEO David Shaw Named Executive Chairman and Chairman of the Board

-

CLINTON, N.J., Jan. 9 /PRNewswire/ -- Ikaria Holdings, Inc., a fully integrated critical care biopharmaceutical company, announced today that Daniel Tasse has been appointed President and Chief Executive Officer. Mr. Tasse succeeds David Shaw, who has served as Chairman and interim CEO since the creation of Ikaria Holdings in March 2007 and will now serve as Executive Chairman and Chairman of the Board.

Mr. Shaw commented, "Daniel is an outstanding fit for the Ikaria opportunity, and vice versa. He has extensive executive management experience in 'academy companies' in the pharmaceutical and life sciences industry, with highly relevant expertise in R&D management, marketing and sales, and other functions in domestic and international markets. We expect to benefit strategically and operationally from Daniel's many years of involvement in both drugs and devices across many therapeutic areas and healthcare settings, including critical care. His leadership capabilities and his knowledge of in- hospital markets will be particularly valuable as Ikaria continues to build an exceptionally strong capability to serve the needs of critically ill patients."

Daniel Tasse stated, "The formation of Ikaria last year created a company with the potential to redefine the critical care industry. With Ikaria's industry-leading INOmax(R) product and a pipeline of unique therapeutic compounds and numerous business development and R&D opportunities, we have a very exciting and unique opportunity available to us. I feel very fortunate to join this team in a leadership position with the goal of building a legendary company in the years ahead."

Mr. Tasse most recently served as the General Manager of Baxter International's $2 billion Pharmaceuticals & Technologies business, a division created by integrating the company's Anesthesia, Critical Care and BioPharma Solutions Business units. Prior to his tenure at Baxter International, Mr. Tasse held management positions at GlaxoSmithKline and Upjohn. He has a B.Sc. in Biochemistry from the University of Montreal.

About Ikaria Holdings, Inc.

Ikaria Holdings, Inc. is a fully integrated biotherapeutics company focused on the development and commercialization of innovative in-hospital pharmaceutical products and drug/device combinations for the critically ill. The company's product, INOmax(R) (nitric oxide) for inhalation, is an FDA- approved drug for the treatment of hypoxic respiratory failure in term and near-term newborns. The drug also is approved by regulatory authorities and used in Canada, Europe, Australia and Latin America. In addition to marketing and selling its INOmax product, Ikaria is engaged in both Phase II trials with Covox(R) (carbon monoxide) for inhalation and Phase I trials with hydrogen sulfide (H2S) for various indications. Ikaria has a staff of over 300 people and is headquartered in Clinton, NJ, with research facilities in Seattle, WA and Madison, WI and manufacturing in Port Allen, LA. For more information on Ikaria, please visit http://www.ikaria.com.

Contacts

Matthew Bennett

Ikaria

908-238-6673

matthew.bennett@ikaria.com

Jason Rando/Catherine Bright

The Ruth Group

646-536-7025/7013

jrando@theruthgroup.com

cbright@theruthgroup.com


'/>"/>
SOURCE Ikaria Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Ikaria to Present at 26th Annual JPMorgan Healthcare Conference
2. Ikaria Founding Scientist Named 2007 MacArthur Fellow
3. New Study Shows Promise for Hydrogen Sulfide in Reducing Heart-Attack Damage, Ikaria Announces
4. SRA Names Timothy J. Atkin Senior Vice President of Global Health Business; Appoints Mike Toner Global Health Unit Chief Financial Officer
5. Mersana Therapeutics Appoints C. Boyd Clarke Chairman of the Board of Directors
6. Chimerix Appoints Neil Frazer, M.B., Ch.B., FRCA, FFPM as Chief Medical Officer
7. Access Pharmaceuticals Appoints Jeffrey B. Davis as CEO
8. Seahorse Bioscience Appoints Former Molecular Devices Executive Dr. Joseph D. Keegan to Board of Directors
9. Kendle Appoints Former MHRA Head of Biologics as Principal Regulatory Affairs Consultant
10. LeMaitre Vascular Appoints Russell D. Hays to Its Board of Directors
11. SGX Pharmaceuticals Appoints Joseph L. Turner to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... Biotech Ltd. ("Sinovac" or the "Company") (NASDAQ: SVA), a leading provider ... that its board of directors has amended its shareholder rights plan. The ... 2017 to March 27, 2018. The amendment was not in response to ... ... Ltd. is a China -based biopharmaceutical company that ...
(Date:3/23/2017)... ... ... to announce it has become the premiere team-building cooking event company in San Diego. ... as Illumina, HP and Qualcomm, and is ranked #1 in its category on Trip Advisor. ... new team building format, a way for teams to not only interact with one another ...
(Date:3/23/2017)... MENLO PARK, Calif., March 23, 2017  BioPharmX ... developing products for the dermatology market, today reported ... Jan. 31, 2017, and will provide an update ... from the year. "We are pleased ... productive year for BioPharmX," said President Anja Krammer. ...
(Date:3/23/2017)... Colo. , March 23, 2017  Agriculture technology ... Series A financing and note conversion to commercialize its ... Planet is focused on developing products that are simultaneously ... $30 million in the last 18 months. This latest ... North Bridge Venture Partners. The company,s ...
Breaking Biology Technology:
(Date:3/23/2017)... Research and Markets has announced the addition of the ... Forecast to 2025" report to their offering. ... The Global Vehicle Anti-Theft System ... over the next decade to reach approximately $14.21 billion by 2025. ... forecasts for all the given segments on global as well as ...
(Date:3/20/2017)... , March 20, 2017 PMD Healthcare ... personal spirometer and Wellness Management System (WMS), a remote, ... Founded in 2010, PMD Healthcare is a Medical Device, ... a mission dedicated to creating innovative solutions that empower ... With that intent focus, PMD developed the first ever ...
(Date:3/7/2017)... BRIGHTON, England , March 7, 2017 Brandwatch ... been chosen by The Prince,s Trust to uncover insights ... insights across The Trust. The UK,s leading youth charity ... track social campaign results and get a better understanding of the ... ...
Breaking Biology News(10 mins):